CStone announces 1st dosed patient in China for advanced GIST trial
Category: #health  By Mateen Dalal  Date: 2019-08-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

CStone announces 1st dosed patient in China for advanced GIST trial

Leading biopharmaceutical expert CStone Pharmaceuticals has reportedly announced the first person in China to be dosed for the Phase I/II bridging trial of Avapritinib, discovered by Blueprint Medicines, a partner of CStone.

This China-based standalone study is a registrational bridging trial including studies of dose-escalation in Phase I and dose-expansion in Phase II, aimed at assessing the efficiency, safety and pharmacokinetics of Avapritinib in patients suffering from metastatic or uresectable GIST (gastrointestinal stromal tumors).

Patients involved in this study are mostly those suffering from PDGFRA D842V- driven GIST, second or third-line GIST or later GIST.

For the uninitiated, GIST is a type of sarcoma, usually found in the wall of the stomach or in the small intestine. GIST is usually detected among patients between 50-80 years of age. Nearly 90% of GIST cases are related to cell growth dysregulation caused by PDGFRA and KIT tyrosine kinases mutation. There are presently no effectual treatments for patients suffering from PDGFRA D842V- driven GIST.

Avapritinib is an orally administered highly selective and potent KIT and PDGFRA inhibitor. Preclinical studies from previously published studies have revealed that Avapritinib shows strong activity against GIST-related PDGFRA and KIT mutant kinases.

Chairman & CEO of CStone, Dr. Frank Jiang has reportedly commented that patients suffering from PDGFRA D842V kinases mutations still lack efficient care even as GIST incident rates continue to rise and expressed CStone’s commitment towards the evolution of ground-breaking therapies designed to fulfill urgent medical needs. He further stated CStone’s wish to follow in the footsteps of their partner Blueprint Medicines, who have submitted an NDA for Avapritinib in the US and an application for marketing authorization in the EU, by giving patients in Greater China access to this innovative precision therapy at the earliest.

CStone’s Chief Medical Officer, Dr. Jason Yang spoke about the data presented from their global Phase I Navigator study of Avapritinib, presented at the ASCO 2019 annual meeting, which showed an 86% objective response rate and promising tolerability in GIST patients with PDGFRA Exon 18 mutations.

Source Credit: http://www.cstonepharma.com/en/html/news/2196.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Taco Bell to introduce its first-ever business school for employees
Taco Bell to introduce its first-ever business school for employees
By Mateen Dalal

The fast-food chain has collaborated with the University of Louisville for starting this project Taco Bell, a US-based chain of fast-food restaurants, is reportedly opening its business school with a vision of helping its employees learn the skills ...

Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
Jubilant Foodworks unveils first chain of Popeyes in Bengaluru, India
By Mateen Dalal

Jubilant Foodworks Ltd, an Indian food service company, has recently announced unveiling the iconic United States’ Fried Chicken brand-Popeyes in India by inaugurating its first store in Bengaluru, India. For the uninitiated, Popeyes Louisiana...

Affinity to trade Burger King business in Japan & South Korea for $1Bn
Affinity to trade Burger King business in Japan & South Korea for $1Bn
By Mateen Dalal

Affinity Equity Partners, one of the largest dedicated Asian private equity firms, is reportedly planning to sell off its Burger King fast-food businesses in Japan and South Korea, in a deal that can offer more than $1 billion, said a credible source...